Predictors for patterns of brain relapse and overall survival in patients with non-small cell lung cancer

被引:13
|
作者
Tang, SGJ
Tseng, CK
Tsay, PK
Chen, CH
Chang, JWC
Pai, PC
Hong, JH
机构
[1] Chang Gung Mem Hosp, Dept Radiat Oncol, Tao Yuan, Taiwan
[2] Chang Gung Univ, Coll Med, Dept Publ Hlth, Tao Yuan, Taiwan
[3] Chang Gung Mem Hosp, Dept Thorac Med, Tao Yuan, Taiwan
[4] Chang Gung Mem Hosp, Dept Med Oncol, Tao Yuan, Taiwan
关键词
brain metastases; brain relapse; lung cancer; predictors; survival;
D O I
10.1007/s11060-004-3725-4
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Our goal was to investigate prognostic factors for different patterns of brain relapse and overall survival so that treatments could be tailored and treatment outcomes improved. We studied 292 patients with non-small cell lung cancer (NSCLC) who had symptomatic, solitary, or multiple brain metastases (isolated or not isolated from extracranial metastases) that had developed early (<= 6 months) or late (>6 months) from initial diagnosis. Factors affecting patterns of relapse and survival were analyzed by univariate and multivariate analyses. Good ECOG performance status (PS) at the time of NSCLC diagnosis was the most important factor that predicted late (rather than early) relapse and improved survival, and was the only factor that predicted isolated brain metastases. Patients whose lungs showed a complete response (CR) to treatment had a higher rate of late brain relapses than non-responders (NR) did (67.3% vs. 7.8%, P<0.001). CR patients also experienced a longer median overall survival than NR patients. Patients with late brain relapses showed better median survival times (18 months vs. 4 months, P<0.0001) than patients with early relapses, and this was an independent factor by Cox regression analysis. Our findings provide a justification for enrolling patients with good PS and controlled lung lesions into clinical trials for the prevention of early, non-isolated brain relapse. More aggressive therapeutic approaches should be applied to patients with late, isolated and solitary relapses to improve both quality and quantity of life.
引用
收藏
页码:153 / 161
页数:9
相关论文
共 50 条
  • [41] EGFR Status, Risk Factors for Brain Metastases and Overall Survival in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients
    Chowdhury, M.
    Hueniken, K.
    Schmid, S.
    Brown, C.
    Khan, K.
    Walia, P.
    Sabouhanian, A.
    Strom, E.
    Herman, J.
    Xu, W.
    Leighl, N.
    Bradbury, P.
    Sacher, A.
    Shepherd, F.
    Liu, G.
    Shultz, D.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S625 - S626
  • [42] Geriatrics predictors of 3-months overall survival and chemotherapy toxicities in older patients with metastatic non-small cell lung cancer
    Gendarme, S.
    Zebachi, S.
    Corre, R.
    Greillier, L.
    Justeau, G.
    Bylicki, O.
    Decroisette, C.
    Auliac, J. B.
    Guisier, F.
    Geier, M.
    Ricordel, C.
    Frelaut, M.
    Paillaud, E.
    Chouaid, C.
    Canoui-Poitrine, F.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1077 - S1077
  • [43] Unstaged non-small cell lung cancer in the United States: Predictors and survival
    Bista, Amir
    Sharma, Sandhya
    Uprety, Dipesh
    Khanal, Amit
    Basnet, Bibhusan
    Shah, Binay Kumar
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [44] Pneumonectomy for non-Small cell lung cancer: predictors of operative morality and survival
    Alexiou, C
    Beggs, D
    Rogers, ML
    Beggs, L
    Asopa, S
    Salama, FD
    EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 2001, 20 (03) : 476 - 480
  • [45] Resistin is associated with overall survival in non-small cell lung cancer patients during nivolumab treatment
    Bonaventura, A.
    Grossi, F.
    Carbone, F.
    Vecchie, A.
    Minetti, S.
    Bardi, N.
    Elia, E.
    Ansaldo, A. M.
    Ferrara, D.
    Rijavec, E.
    Dal Bello, M. G.
    Rossi, G.
    Biello, F.
    Tagliamento, M.
    Alama, A.
    Coco, S.
    Spallarossa, P.
    Dallegri, F.
    Genova, C.
    Montecucco, F.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2020, 22 (09): : 1603 - 1610
  • [46] Bone Metastases and Overall Survival in Patients with Metastatic Non-Small Cell Lung Cancer Treated with Pembrolizumab
    Das, P.
    Zhao, S.
    Wei, L.
    Miah, A.
    Li, M.
    Lopez, G.
    Patel, S.
    Johns, A.
    Grogan, M.
    Bertino, E.
    He, K.
    Shields, P.
    Carbone, D.
    Otterson, G.
    Presley, C.
    Owen, D.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S293 - S293
  • [47] Sarcopenia Is Associated With Worse Overall Survival in Patients With Locally Advanced Non-Small Cell Lung Cancer
    Grendarova, P.
    Arora, R.
    Bebb, G. D.
    D'Silva, A.
    Banerjee, R. N.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2016, 96 (02): : S201 - S202
  • [48] The association between body composition and overall survival in patients with advanced non-small cell lung cancer
    Fu, Liang
    Ding, Haiming
    Mo, Liupei
    Pan, Xiaoyu
    Feng, Lijuan
    Wen, Shenglian
    Lan, Qiaoqing
    Long, Liling
    SCIENTIFIC REPORTS, 2025, 15 (01):
  • [49] A nomogram for predicting overall survival in patients with resected non-small cell lung cancer treated with chemotherapy
    Zeng, Yuan
    Mayne, Nicholas
    Yang, Chi-Fu Jeffrey
    Liu, Jun
    Cui, Fei
    Li, Jingpei
    Liang, Wenhua
    He, Jianxing
    TRANSLATIONAL LUNG CANCER RESEARCH, 2021, 10 (04) : 1690 - +
  • [50] SARCOPENIA IS ASSOCIATED WITH WORSE OVERALL SURVIVAL IN PATIENTS WITH LOCALLY ADVANCED NON-SMALL CELL LUNG CANCER
    Grendarova, Petra
    Arora, Rahul
    Bebb, Gwyn
    D'Silva, Adrijana
    Robyn, Banerjee
    RADIOTHERAPY AND ONCOLOGY, 2016, 120 : S87 - S87